文献速递白血病

MS4A3通过增强共同β链细胞因子受体内吞促进慢性髓性白血病分化

MS4A3 promotes differentiation in chronic myeloid leukemia by enhancing common β-chain cytokine receptor endocytosis.
PubMed 文献 · Blood · 2022-01-01

本研究通过已发表CML转录组Meta分析发现,MS4A3低表达是LSPC静息、BCR-ABL1非依赖及急变期的普遍特征;MS4A3经GM-CSF/IL-3刺激促进共同β链细胞因子受体内吞、增强下游信号与分化,其敲低或缺失促进TKI耐药与白血病发生,外源MS4A3蛋白可促进分化。

要点

  • MS4A3低表达是CML干/祖细胞静息、BCR-ABL1非依赖和急变期的普遍特征。
  • MS4A3经GM-CSF/IL-3刺激促进共同β链细胞因子受体内吞并增强分化信号。
  • 敲低或缺失MS4A3促进TKI耐药和CML细胞存活,外源MS4A3蛋白促进分化。

核心结论

  • MS4A3调控髓系分化细胞因子反应,为CML静息和急变期分化阻滞提供统一机制。
  • 促进MS4A3再表达或递送外源MS4A3可能有助于体内清除LSPC。

研究设计与样本

  • 对已发表CML转录组进行Meta分析,并结合体外和体内功能实验。

主要发现

  • MS4A3低表达是LSPC静息、BCR-ABL1非依赖和急变期的普遍特征。
  • MS4A3受异常甲基化和MECOM-C/EBPε轴抑制。
  • MS4A3并非G1/S期抑制因子,而是在GM-CSF/IL-3刺激下促进共同β链细胞因子受体内吞。
  • 敲低或缺失MS4A3/Ms4a3促进体外CML细胞TKI耐药和存活,并增强体内白血病发生。
  • 靶向递送外源MS4A3蛋白促进分化。

临床怎么用

  • 作者认为促进MS4A3再表达或递送外源MS4A3可能有助于体内清除LSPC。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The chronic phase of chronic myeloid leukemia (CP-CML) is characterized by the excessive production of maturating myeloid cells. As CML stem/progenitor cells (LSPCs) are poised to cycle and differentiate, LSPCs must balance conservation and differentiation to avoid exhaustion, similar to normal hematopoiesis under stress. Since BCR-ABL1 tyrosine kinase inhibitors (TKIs) eliminate differentiating cells but spare BCR-ABL1-independent LSPCs, understanding the mechanisms that regulate LSPC differentiation may inform strategies to eliminate LSPCs. Upon performing a meta-analysis of published CML transcriptomes, we discovered that low expression of the MS4A3 transmembrane protein is a universal characteristic of LSPC quiescence, BCR-ABL1 independence, and transformation to blast phase (BP). Several mechanisms are involved in suppressing MS4A3, including aberrant methylation and a MECOM-C/EBPε axis. Contrary to previous reports, we find that MS4A3 does not function as a G1/S phase inhibitor but promotes endocytosis of common β-chain (βc) cytokine receptors upon GM-CSF/IL-3 stimulation, enhancing downstream signaling and cellular differentiation. This suggests that LSPCs downregulate MS4A3 to evade βc cytokine-induced differentiation and maintain a more primitive, TKI-insensitive state. Accordingly, knockdown (KD) or deletion of MS4A3/Ms4a3 promotes TKI resistance and survival of CML cells ex vivo and enhances leukemogenesis in vivo, while targeted delivery of exogenous MS4A3 protein promotes differentiation. These data support a model in which MS4A3 governs response to differentiating myeloid cytokines, providing a unifying mechanism for the differentiation block characteristic of CML quiescence and BP-CML. Promoting MS4A3 reexpression or delivery of ectopic MS4A3 may help eliminate LSPCs in vivo.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Zhao H, Pomicter AD, Eiring AM, et al. MS4A3 promotes differentiation in chronic myeloid leukemia by enhancing common β-chain cytokine receptor endocytosis. Blood. 2022. PMID: 34780648. doi:10.1182/blood.2021011802

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。